Corcept Therapeutics
$116.23Change from previous close: +1.93%Absolute change: +$2.20
At a glance
- Revenue growth
- +12.79%
- 2025 vs 2024
- Net income growth
- −29.43%
- 2025 vs 2024
- Net margin
- 13.1%
- 2024: 20.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total assets | 889 | 815 | 837 | 824 | 802 | — |
| Current assets | 440 | 426 | 485 | 541 | 443 | — |
| Cash and equivalents | 111 | 109 | 120 | 125 | 103 | — |
| Short-term investments | 197 | 229 | 252 | 297 | 239 | — |
| Receivables | 76.9 | 39.1 | 59.8 | 69.6 | 64.6 | — |
| Inventory | 13.2 | 12.9 | 12.9 | 12.3 | 12.3 | — |
| Net property, plant and equipment | 12.0 | 10.4 | 6.5 | 6.9 | 7.3 | — |
| Long-term investments | 236 | 177 | 160 | 103 | 173 | — |
| Current liabilities | 154 | 149 | 166 | 172 | 145 | — |
| Accounts payable | 14.9 | 33.3 | 40.4 | 34.4 | 23.5 | — |
| Total debt | 9.4 | 9.6 | 6.1 | 6.4 | 6.6 | — |
| Total liabilities | 183 | 177 | 189 | 192 | 166 | — |
| Total equity (incl. minority) | 706 | 638 | 648 | 632 | 636 | — |
| Retained earnings | 655 | 612 | 643 | 619 | 599 | — |